دورية أكاديمية
أعرض في EDS

Rethinking Cervical Cancer Screening in Brazil Post COVID-19: A Global Opportunity to Adopt Higher Impact Strategies.

التفاصيل البيبلوغرافية
العنوان: Rethinking Cervical Cancer Screening in Brazil Post COVID-19: A Global Opportunity to Adopt Higher Impact Strategies.
المؤلفون: Ribeiro A; Department of Pharmacy, Faculty of Health Sciences, University of Brasília (UNB), Brasília, District Federal, Brazil. ana-ribeiro.dantas@fiocruz.br.; Center for Epidemiology and Health Surveillance, Oswaldo Cruz Foundation (FIOCRUZ), Brasília, District Federal, Brazil., Corrêa F; Cancer Early Detection Division, Brazilian National Cancer Institute (INCA), Rio de Janeiro, Brazil., Migowski A; Cancer Early Detection Division, Brazilian National Cancer Institute (INCA), Rio de Janeiro, Brazil., Leal A; General Coordination of Specialized Care, Health Care Secretariat, Ministry of Health (MS), Brasília, District Federal, Brazil., Martins S; Center for Epidemiology and Health Surveillance, Oswaldo Cruz Foundation (FIOCRUZ), Brasília, District Federal, Brazil., Raiol T; Center for Epidemiology and Health Surveillance, Oswaldo Cruz Foundation (FIOCRUZ), Brasília, District Federal, Brazil., Marques CP; Center for Epidemiology and Health Surveillance, Oswaldo Cruz Foundation (FIOCRUZ), Brasília, District Federal, Brazil.; Department of Public Health, Faculty of Ceilândia, University of Brasília (UNB), Brasília, District Federal, Brazil., Torres KL; Center for Epidemiology and Health Surveillance, Oswaldo Cruz Foundation (FIOCRUZ), Brasília, District Federal, Brazil.; Amazon State Oncology Control Foundation (FCECON), Manaus, Amazonas, Brazil., Novetsky AP; Rutgers New Jersey Medical School (NJMS), Newark, New Jersey.; Rutgers Cancer Institute of New Jersey (CINJ), New Brunswick, New Jersey., Marcus JZ; Rutgers New Jersey Medical School (NJMS), Newark, New Jersey., Wentzensen N; Clinical Epidemiology Unit, Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, Maryland., Schiffman M; Clinical Epidemiology Unit, Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, Maryland., Rodriguez AC; Clinical Epidemiology Unit, Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, Maryland., Gage JC; Clinical Epidemiology Unit, Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, Maryland.
المصدر: Cancer prevention research (Philadelphia, Pa.) [Cancer Prev Res (Phila)] 2021 Oct; Vol. 14 (10), pp. 919-926.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101479409 Publication Model: Print Cited Medium: Internet ISSN: 1940-6215 (Electronic) Linking ISSN: 19406215 NLM ISO Abbreviation: Cancer Prev Res (Phila) Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Philadelphia, PA : American Association for Cancer Research
مواضيع طبية MeSH: COVID-19/*complications , Cytodiagnosis/*methods , Early Detection of Cancer/*methods , Papillomaviridae/*isolation & purification , Papillomavirus Infections/*complications , SARS-CoV-2/*isolation & purification , Uterine Cervical Neoplasms/*diagnosis, Brazil/epidemiology ; DNA, Viral/analysis ; DNA, Viral/genetics ; Female ; Humans ; Papillomavirus Infections/genetics ; Papillomavirus Infections/virology ; Uterine Cervical Neoplasms/epidemiology ; Uterine Cervical Neoplasms/virology
مستخلص: The World Health Organization global call to eliminate cervical cancer encourages countries to consider introducing or improving cervical cancer screening programs. Brazil's Unified Health System (SUS) is among the world's largest public health systems offering free cytology testing, follow-up colposcopy, and treatment. Yet, health care networks across the country have unequal infrastructure, human resources, equipment, and supplies resulting in uneven program performance and large disparities in cervical cancer incidence and mortality. An effective screening program needs multiple strategies feasible for each community's reality, facilitating coverage and follow-up adherence. Prioritizing those at highest risk with tests that better stratify risk will limit inefficiencies, improving program impact across different resource settings. Highly sensitive human papillomavirus (HPV)-DNA testing performs better than cytology and, with self-collection closer to homes and workplaces, improves access, even in remote regions. Molecular triage strategies like HPV genotyping can identify from the same self-collected sample, those at highest risk requiring follow-up. If proven acceptable, affordable, cost-effective, and efficient in the Brazilian context, these strategies would increase coverage while removing the need for speculum exams for routine screening and reducing follow-up visits. SUS could implement a nationwide organized program that accommodates heterogenous settings across Brazil, informing a variety of screening programs worldwide.
(©2021 American Association for Cancer Research.)
References: Estimate/2020 – cancer incidence in Brazil. 2019.
Lei J, Ploner A, Elfstrom KM, Wang J, Roth A, Fang F, et al. HPV vaccination and the risk of invasive cervical cancer. N Engl J Med. 2020;383:1340–8.
Vale DB, Menin TL, Braganca JF, Teixeira JC, Cavalcante LA, Zeferino LC. Estimating the public health impact of a national guideline on cervical cancer screening: an audit study of a program in Campinas, Brazil. BMC Public Health. 2019;19:1492.
Pereira RHM, Braga CKV, Servo LMS, Serra B, Amaral P, Gouveira N, et al. Mobilidade urbana e o acesso ao Sistema de saúde para casos suspeitos e graves de COVID-19 nas vinte maiores cidades do Brasil: Nota Técnica No. 14. 2020.
Villain P, Carvalho AL, Lucas E, Mosquera I, Zhang L, Muwonge R, et al. Cross-sectional survey of the impact of the COVID-19 pandemic on cancer screening programs in selected low- and middle-income countries: study from the IARC COVID-19 impact study group. Int J Cancer. 2021;149:97–107.
de Souza WM, Buss LF, Candido DDS, Carrera JP, Li S, Zarebski AE, et al. Epidemiological and clinical characteristics of the COVID-19 epidemic in Brazil. Nat Hum Behav. 2020;4:856–65.
Nota Técnica - DIDEPRE/CONPREV/INCA - 30/3/2020 Detecção precoce de câncer durante a pandemia de Covid-19. 2020.
Nota Técnica – DIDEPRE/CONPREV/INCA Rastreamento de câncer durante a pandemia de COVID-19 09/07/2020. 2020.
Ciavattini A, Delli Carpini G, Giannella L, Arbyn M, Kyrgiou M, Joura EA, et al. European Federation for Colposcopy (EFC) and European Society of Gynaecological Oncology (ESGO) joint considerations about human papillomavirus (HPV) vaccination, screening programs, colposcopy, and surgery during and after the COVID-19 pandemic. Int J Gynecol Cancer. 2020;30:1097–100.
Schiffman M, Doorbar J, Wentzensen N, de Sanjose S, Fakhry C, Monk BJ, et al. Carcinogenic human papillomavirus infection. Nat Rev Dis Primers. 2016;2:16086.
Wentzensen N, Schiffman M, Palmer T, Arbyn M. Triage of HPV positive women in cervical cancer screening. J Clin Virol. 2016;76:S49–55.
Brazilian Cervical Cancer Screening Guidelines. 2016.
Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 2010;11:249–57.
Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007;357:1579–88.
Nanda K, McCrory DC, Myers ER, Bastian LA, Hasselblad V, Hickey JD, et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med. 2000;132:810–9.
Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ. 2008;337:a1754.
Derchain S, Teixeira JC, Zeferino LC. Organized, population-based cervical cancer screening program: it would be a good time for Brazil now. Rev Bras Ginecol Obstet. 2016;38:161–3.
Teixeira JC, Vale DB, Braganca JF, Campos CS, Discacciati MG, Zeferino LC. Cervical cancer screening program based on primary DNA-HPV testing in a Brazilian city: a cost-effectiveness study protocol. BMC Public Health. 2020;20:576.
Zeferino LC, Bastos JB, Vale D, Zanine RM, Melo Y, Primo W, et al. Guidelines for HPV-DNA testing for cervical cancer screening in Brazil. Rev Bras Ginecol Obstet. 2018;40:360–8.
Levi JE, Martins TR, Longatto-Filho A, Cohen DD, Cury L, Fuza LM, et al. High-risk HPV testing in primary screening for cervical cancer in the Public Health System, Sao Paulo, Brazil. Cancer Prev Res. 2019;12:539–46.
Primo W, Speck NMG, Roteli-Martins CM, Fernandes CE, Silva Filho ALD. Call to eliminate cervical cancer in the next decade with a focus on Brazil. Rev Bras Ginecol Obstet. 2021;43:1–2.
Canfell K, Caruana M, Gebski V, Darlington-Brown J, Heley S, Brotherton J, et al. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: results of the Compass pilot randomised trial. PLoS Med. 2017;14:e1002388.
Kyrgiou M, Arbyn M, Bergeron C, Bosch FX, Dillner J, Jit M, et al. Cervical screening: ESGO-EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC). Br J Cancer. 2020;123:510–7.
Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, et al. Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018;320:674–86.
Liverani CA, Di Giuseppe J, Giannella L, Delli Carpini G, Ciavattini A. Cervical cancer screening guidelines in the postvaccination era: review of the literature. J Oncol. 2020;2020:8887672.
Koliopoulos G, Arbyn M, Martin-Hirsch P, Kyrgiou M, Prendiville W, Paraskevaidis E. Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies. Gynecol Oncol. 2007;104:232–46.
Polman NJ, Snijders PJF, Kenter GG, Berkhof J, Meijer C. HPV-based cervical screening: rationale, expectations and future perspectives of the new Dutch screening programme. Prev Med. 2019;119:108–17.
Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006;119:1095–101.
Hammer A, Demarco M, Campos N, Befano B, Gravitt PE, Cheung L, et al. A study of the risks of CIN3+ detection after multiple rounds of HPV testing: Results of the 15-year cervical cancer screening experience at Kaiser Permanente Northern California. Int J Cancer. 2020;147:1612–20.
Gage JC, Schiffman M, Katki HA, Castle PE, Fetterman B, Wentzensen N, et al. Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test. J Natl Cancer Inst. 2014;106:dju153.
Dijkstra MG, van Zummeren M, Rozendaal L, van Kemenade FJ, Helmerhorst TJ, Snijders PJ, et al. Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands. BMJ. 2016;355:i4924.
Gilham C, Sargent A, Kitchener HC, Peto J. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT. Health Technol Assess. 2019;23:1–44.
Arbyn M, Smith SB, Temin S, Sultana F, Castle PCollaboration on Self-Sampling and HPV Testing, et al. Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses. BMJ. 2018;363:k4823.
Torres KL, Marino JM, Pires Rocha DA, de Mello MB, de Melo Farah HH, Reis RDS, et al. Self-sampling coupled to the detection of HPV 16 and 18 E6 protein: a promising option for detection of cervical malignancies in remote areas. PLoS One. 2018;13:e0201262.
Relatório de Recomendação No. 497 - Citologia em meio líquido para rastreamento de câncer de colo de útero e lesões precursoras. 2019.
Wentzensen N, Walker JL, Gold MA, Smith KM, Zuna RE, Mathews C, et al. Multiple biopsies and detection of cervical cancer precursors at colposcopy. J Clin Oncol. 2015;33:83–9.
Gage JC, Schiffman M, Hunt WC, Joste N, Ghosh A, Wentzensen N, et al. Cervical histopathology variability among laboratories: a population-based statewide investigation. Am J Clin Pathol. 2013;139:330–5.
Malpica A, Matisic JP, Niekirk DV, Crum CP, Staerkel GA, Yamal JM, et al. Kappa statistics to measure interrater and intrarater agreement for 1790 cervical biopsy specimens among twelve pathologists: qualitative histopathologic analysis and methodologic issues. Gynecol Oncol. 2005;99:S38–52.
Buss LF, Levi JE, Longatto-Filho A, Cohen DD, Cury L, Martins TR, et al. Attendance for diagnostic colposcopy among high-risk human papillomavirus positive women in a Brazilian feasibility study. Int J Gynaecol Obstet. 2021;152:72–7.
Madalena Ribeiro C, Dos Santos Silva I, Eluf Neto J, Pereira Baltar Cury LC, Azevedo E Silva G. Follow-up of women screened for cervical cancer in São Paulo, Brazil: an analysis of the times to diagnostic investigation and treatment. Cancer Epidemiol. 2021;72:101940.
Demarco M, Hyun N, Carter-Pokras O, Raine-Bennett TR, Cheung L, Chen X, et al. A study of type-specific HPV natural history and implications for contemporary cervical cancer screening programs. EClinicalMedicine. 2020;22:100293.
de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11:1048–56.
Wentzensen N, Clarke MA, Bremer R, Poitras N, Tokugawa D, Goldhoff PE, et al. Clinical evaluation of human papillomavirus screening with p16/Ki-67 dual stain triage in a large organized cervical cancer screening program. JAMA Intern Med. 2019;179:881–8.
Peeters E, Wentzensen N, Bergeron C, Arbyn M. Meta-analysis of the accuracy of p16 or p16/Ki-67 immunocytochemistry versus HPV testing for the detection of CIN2+/CIN3+ in triage of women with minor abnormal cytology. Cancer Cytopathol. 2019;127:169–80.
Wentzensen N, Lahrmann B, Clarke MA, Kinney W, Tokugawa D, Poitras N, et al. Accuracy and efficiency of deep-learning-based automation of dual stain cytology in cervical cancer screening. J Natl Cancer Inst. 2021;113:72–79.
Clarke MA, Gradissimo A, Schiffman M, Lam J, Sollecito CC, Fetterman B, et al. Human papillomavirus DNA methylation as a biomarker for cervical precancer: consistency across 12 genotypes and potential impact on management of HPV-positive women. Clin Cancer Res. 2018;24:2194–202.
Hu L, Bell D, Antani S, Xue Z, Yu K, Horning MP, et al. An observational study of deep learning and automated evaluation of cervical images for cancer screening. J Natl Cancer Inst. 2019;111:923–32.
Introducing and scaling up testing for human papillomavirus as part of a comprehensive programme for prevention and control of cervical cancer: a step-by-step guide. 2020.
WHO guidelines for the use of thermal ablation for cervical pre-cancer lesions. 2019.
Naud PS, Muwonge R, Passos EP, Magno V, Matos J, Sankaranarayanan R. Efficacy, safety, and acceptability of thermocoagulation for treatment of cervical intraepithelial neoplasia in a hospital setting in Brazil. Int J Gynaecol Obstet. 2016;133:351–4.
Perkins RB, Guido RS, Castle PE, Chelmow D, Einstein MH, Garcia F, et al. 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2020;24:102–31.
Gravitt PE, Rositch AF, Jurczuk M, Meza G, Carillo L, Jeronimo J, et al. Integrative systems praxis for implementation research (INSPIRE): an implementation methodology to facilitate the global elimination of cervical cancer. Cancer Epidemiol Biomarkers Prev. 2020;29:1710–9.
World Health Assembly Resolution WHA73.2 (2020).
Ginsburg O, Basu P, Kapambwe S, Canfell K. Eliminating cervical cancer in the COVID-19 era. Nat Cancer. 2021;2:133–4.
المشرفين على المادة: 0 (DNA, Viral)
تواريخ الأحداث: Date Created: 20211005 Date Completed: 20211018 Latest Revision: 20211018
رمز التحديث: 20221213
DOI: 10.1158/1940-6207.CAPR-21-0110
PMID: 34607876
قاعدة البيانات: MEDLINE
الوصف
تدمد:1940-6215
DOI:10.1158/1940-6207.CAPR-21-0110